Pfizer and BioNTech announced Thursday they are developing a Covid-19 booster shot intended to target the delta variant.
Clinical studies could begin as early as August, subject to regulatory approvals.

The companies said although they believe a third shot of their current two-dose vaccine has the potential to preserve the “highest levels” of protection against all currently known variants, including delta, they are “remaining vigilant” and developing an updated version of the vaccine.

As seen in real world evidence released from the Israel Ministry of Health, vaccine efficacy has declined six months post-vaccination, at the same time that the Delta variant is becoming the dominate variant in the country,” the companies said in a written statement.

These findings are consistent with an ongoing analysis from the companies’ Phase 3 study,” they said. “That is why we have said, and we continue to believe that it is likely, based on the totality of the data we have to date, that a third dose may be needed within 6 to 12 months after full vaccination.


On Monday, Israeli officials reported a decrease in the effectiveness of the Pfizer-BioNTech vaccine in preventing infections and symptomatic illness.

https://www.cnbc.com/2021/07/08/pfizer-says-it-is-developing-a-covid-booster-shot-to-target-the-highly-transmissible-delta-variant.html